Sun Pharma gets non-exclusive rights to sell Kidney disease treatment drug in India

India has the second-highest number of people with diabetes after China. Over 40% of the patients with diabetes will develop chronic kidney disease, according to a study by The Indian Chronic Kidney Disease (ICKD).

A phase-III clinical trial program of Finerenone showed that it significantly reduced the risk of composite Cardio Vascular outcome by 14%.

Kirti Ganorkar, CEO of Sun Pharma's India business said that the collaboration will provide patients access to a new treatment, which slows down the progression of chronic kidney disease and reduces the risk of kidney failure associated with Type-2 diabetes.

"Through our partnership with Sun Pharma, we are advancing Bayer’s commitment of making healthcare accessible to as many patients as possible. India has a high incidence of diabetes and associated renal and cardiac conditions," said Shweta Rai, Country Division Head of Bayer's Pharma business in South Asia.

In an interaction with CNBC-TV18 post its September quarter results, Group CFO CS Muralidharan said that the company has maintained its financial year 2024 revenue guidance.

Shares of Sun Pharma are trading 1.1% lower at ₹1,298.70. The stock has risen 25% over the last 12 months.